Healthcare Update: Mayne Pharma & IDT

Scott Power

Morgans

Mayne Pharma has come under a fair bit of selling pressure following further investigations into price fixing for some of their generic drugs. The company reported that impact on their earnings would be minimal and the share price recovered a little bit on the back of that, but at one point it was down 20%. We do not cover the stock formally, but did publish recently on IDT Australia, a smaller version of Mayne. IDT recently announced that they've met the pre-conditions to sell one of their non-core assets and will now focus purely on being a specialist generic drug manufacturer. Click below for our short video covering Mayne and IDT, as well as overviews on Nanosonics and Sirtex. (VIEW LINK)


3 stocks mentioned

Scott Power
Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.